|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Monoclonal antibody for RSV | | |
| **Criteria Subtitle** | Synagis (palivizumab) | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred |  | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code(s) | Type of Code (GCNSeqNo, HICL, NDC) |
| SYNAGIS | 059245 | GCNSeqNo |
| SYNAGIS | 059246 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0998 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 0999 |
| N | 1235 |
| 2 | 0999 |  | Select | What is the patient’s diagnosis? | Prematurity | 1000 |
| Chronic Lung Disease | 2000 |
| Congenital Heart Disease | 3000 |
| Congenital abnormalities of the airway or neuromuscular disease | 4000 |
| Heart Transplant | 5000 |
| Immunocompromised | 6000 |
| Other | 1235 |
| 3 | 1000 |  | Select | Is the patient an infant born before 29 weeks, 0 day’s gestations who is less than 12 months of age at the start of Respiratory Syncytial Virus (RSV) season? | Y | 1231 |
| N | 1235 |
| 4 | 2000 |  | Select | What is the infant’s gestation age and current age? | Infants born at less than 32 weeks AND is currently less than 12 months of age | 2001 |
| Infants born at less than 32 weeks  AND is currently between 12 to 24 months of age | 2002 |
| Other | 1235 |
| 5 | 2001 |  | Select | Has the patient required greater than 21 percent oxygen for at least the first 28 DAYS after birth? | Y | 1231 |
| N | 1235 |
| 6 | 2002 |  | Select | Has the patient required at least 28 days of greater than 21 percent oxygen after birth and continues to require supplemental oxygen, diuretics, or chronic systemic corticosteroid therapy within 6 months of the start of the second Respiratory Syncytial Virus (RSV) season? | Y | 1231 |
| N | 1235 |
| 7 | 3000 |  | Select | Is the patient an infant who is less than 12 months of age with a diagnosis of hemodynamically significant heart disease who will most likely benefit from immunoprophylaxis? | Y | 3001 |
| N | 1235 |
| 8 | 3001 |  | Select | Please select the patient’s diagnosis. | Infants with acyanotic heart disease receiving drugs to control congestive  heart failure and who will require surgery | 1231 |
| Infants with moderate to severe pulmonary hypertension receiving drugs to control pulmonary hypertension | 1231 |
| Infants with a cyanotic heart defect who are prescribed therapy in  consultation with a pediatric cardiologist | 1231 |
| Other | 1235 |
| 9 | 4000 |  | Select | Is the patient less than 12 months of age with a diagnosis of a neuromuscular condition that compromises  handling of respiratory secretions? | Y | 1231 |
| N | 1235 |
| 10 | 5000 |  | Select | Is the patient less than 24 months of age who has had a heart transplant during Respiratory Syncytial Virus (RSV) season? | Y | 1231 |
| N | 1235 |
| 11 | 6000 |  | Select | Is the patient less than 24 months of age who has a diagnosis that supports they are profoundly immunocompromised during the Respiratory Syncytial Virus (RSV) season (e.g. chemotherapy)? | Y | 1231 |
| N | 1235 |
| 12 | 1231 |  | Select and Free Text | Has the provider submitted documentation that the patient has not had Respiratory Syncytial Virus (RSV) during the current season?  If yes, please submit documentation. | Y | 1232 |
| N | 1235 |
| 13 | 1232 |  | Select | Is the medication being requested for use during the Respiratory Syncytial Virus (RSV) season AND not exceeding 1 dose per month (or 5 doses per single RSV season)?    Please note: The 2023-2024 RSV Season is November 1st to March 31st. | Y | END (Pending Manual Review) |
| N | 1235 |
| 14 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: Valid through length of request

|  |  |
| --- | --- |
| **Last Approved** | 10/13/2023 |
| **Other** |  |